Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025MedicinaOpen Access

Repurposing Metformin in Precision Oncology: Mechanistic Insights, Biomarker-Guided Strategies, and Translational Imperatives

View Full Paper
Ask AI
Bookmark
Share

Authors

SKShehla Shafi KhanIRImran Rashid RangrazeAWAdil Farooq Wali

Discussion

Loading...

Member takes

Overview

This review evaluates metformin’s potential as a cancer treatment, highlighting biomarkers and clinical challenges.

Key Points

  • Metformin shows potential anticancer effects in various models, yet its clinical outcomes are variable due to tumor heterogeneity.
  • Key evidence suggests metformin inhibits cancer growth by enhancing immune responses and altering cellular metabolism.
  • A structured literature search identified 63 studies examining metformin’s role in oncology from 2015 to 2025.
  • Addressing biomarker selection in clinical trials is vital for defining metformin’s efficacy in precision medicine.

Cite This Study

Khan et al. (2025) studied this question.

synapsesocial.com/papers/68c239a3b210217d6477cef1https://doi.org/10.3390/medicina61091577
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Metformin Beyond Diabetes: A Precision Gerotherapeutic and Immunometabolic Adjuvant for Aging and Cancer2025
  2. 2Editorial: Emerging horizons of metformin: exploring recent advances and addressing challenges in research and clinical utilization2025
  3. 3Mapping the current research landscape of metformin in cancer based on bibliometric analysis2025
  4. 4Repurposing Metformin: An Update On Mechanism And Exploring Therapeutic Horizons2025
  5. 5Metformin for the treatment of breast cancer: a scoping review of randomized clinical trials2025